Mandard-TRG |
1 |
No residual cancer |
2 |
Rare residual cancer cells |
3 |
Fibrosis outgrowing residual cancer |
4 |
Residual cancer outgrowing fibrosis |
5 |
Absence of regressive changes |
JGCA-TRG |
0 |
No evidence of effect |
1a |
Viable tumor cells occupy more than 2/3 of the tumorous area |
1b |
Viable tumor cells remain in more than 1/3 but less than 2/3 of the tumorous area |
2 |
Viable tumor cells remain in less than 1/3 of the tumorous area |
3 |
No viable tumor cells remain |
CAP-TRG |
0 |
No viable cancer cells (complete response) |
1 |
Single cells or small groups of cancer cells (moderate response) |
2 |
Residual cancer outgrown by fibrosis (minimal response) |
3 |
Minimal or no tumor killed or extensive residual cancer (poor response) |
China-TRG |
Severe response |
Tumor cells completely disappear or very few highly regressive residue exist with obvious scarring and varying inflammation |
Moderate response |
Most tumor cells degenerate and necrosis with obvious stroma fibrosis and inflammation |
Mild response |
Absence of or slight necrosis and degeneration of tumor cells accompanied by mild stroma fibrosis and inflammation |
Becker-TRG |
1a |
No residual tumor/tumor bed |
1b |
<10% residual tumor/tumor bed |
2 |
10–50% residual tumor/tumor bed |
3 |
>50% residual tumor/tumor bed |